Issues in combination antiretroviral therapy: a review

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Human immunodeficiency virus (HIV) infection involves persistent high viral burden and replication.
• Antiretroviral monotherapy provides benefits, but they are limited in duration and completeness.
• Drug resistance and viral mutation are significant challenges in managing HIV disease.

Purpose of the Study:

• To outline the goals of combination antiretroviral therapy for HIV.
• To discuss various agents used in combination therapy.
• To provide guidance on initiating combination therapy for different patient profiles.

Main Methods:

• Review of existing antiretroviral agents and their combinations.
• Analysis of treatment goals including viral load reduction, toxicity mitigation, and resistance prevention.
• Evaluation of patient criteria for initiating combination therapy.

Main Results:

• Combination therapy aims to reduce viral replication, toxicity, and resistance.
• Zidovudine is a central component in current monotherapy and combination regimens.
• Various classes of drugs, including nucleoside analogues, non-nucleoside reverse-transcriptase inhibitors, and protease inhibitors, are explored.

Conclusions:

• Combination therapy is recommended for treatment-naive patients with low CD4+ counts or symptoms, and for those on zidovudine monotherapy experiencing disease progression.
• The decision for combination therapy requires a personalized approach between patient and practitioner due to varying clinical trial results.
• Optimizing HIV treatment involves strategic combinations to improve long-term outcomes and manage drug resistance.